Open Access Open Access  Restricted Access Subscription or Fee Access

Time to include buprenorphine-naloxone combination in the WHO model list of essential medicines

Yatan Pal Singh Balhara, MBBS, MD, DNB, MNAMS


No abstract


opioid dependence, Buprenorphine, Buprenorphine/naloxone

Full Text:



WHO: WHO Model List of Essential Medicines—18th List. World Health Organization, 2013.

Systematic review of the safety of buprenorphine, methadone and naltrexone. Department of Therapeutics and Medicines, Center for the AIDS Programme of Research in South Africa, Congella, South Africa, 2007. Available at Accessed July 12, 2013.

Grissinger M: Keeping patients safe from methadone overdoses. P T. 2011; 36: 462-466.

Mattick RP, Kimber J, Breen C, et al.: Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2008: CD002207.

Yokell MA, Zaller ND, Green TC, et al.: Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: An international review. Curr Drug Abuse Rev. 2011; 4: 28-41.

Orman JS, Keating GM: Buprenorphine/naloxone: A review of its use in the treatment of opioid dependence. Drugs. 2009; 69: 577-607.

United States Substance Abuse and Mental Health Services Administration. Treatment Improvement Protocol 40 (TIP 40): Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction; 2004.

Schackman BR, Leff JA, Polsky D, et al.: Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care. J Gen Intern Med. 2012; 27: 669-676.

WHO: The Global Burden of Disease: 2004 Update. Switzerland: World Health Organization, 2008.



  • There are currently no refbacks.